The Skin Cancer Drugs Clinical Pipeline 2025
Release Date: Q1' 2025
Number of Candidates: 97
Synopsis: Skin cancer, the uncontrolled growth of abnormal skin cells, is among the most common types of cancer. With the exception of melanoma, most skin cancers are not life threatening. However, early diagnosis and treatment are critical to avoid functional or cosmetic deformities that can result from the invasion and damage of nearby tissues and organs.
Although surgery is the most common treatment for skin cancer, drugs – including chemotherapy, immunotherapy and targeted agents – are widely used for treating advanced forms of skin cancer. Drug developers are investing heavily in new drug development programs for skin cancer, primarily in the areas of melanoma, BCC (Basal Cell Carcinoma) and SCC (Squamous Cell Carcinoma), with several promising candidates in the late stages of the clinical pipeline.
The “Skin Cancer Drugs Pipeline 2025” excel sheet presents a look at the major drug candidates currently in the clinical pipeline.
The data-set is delivered in an Excel sheet covering clinical drug development pipeline for the skin cancer drugs market, profiling 97 future candidates.
The data-set is delivered in an Excel sheet covering clinical drug development pipeline for the skin cancer drugs market, profiling 97 future candidates.
For a Sample and Inquiries please contact [email protected]
Pricing: The pipeline excel data sheet is available for the following price:
Single User License: USD 800
Company Wide License (Single Site): USD 1,200
Company Wide License (Global Site): USD 2,000
Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories:
List of Companies Mentioned:
The following companies and organizations have been mentioned in the pipeline:
Pricing: The pipeline excel data sheet is available for the following price:
Single User License: USD 800
Company Wide License (Single Site): USD 1,200
Company Wide License (Global Site): USD 2,000
Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories:
- Candidate (Name)
- Drug Developer(s)
- Indication/Therapeutic Area(s)
- Actinic Keratosis
- BCC (Basal Cell Carcinoma)
- CTCL (Cutaneous T-Cell Lymphoma)
- Kaposi's Sarcoma
- MCC (Merkel Cell Carcinoma)
- Melanoma
- Multiple Skin Cancers
- SCC (Squamous Cell Carcinoma)
- Soft Tissue Sarcoma
- Classification(s)
- Combination Therapy
- Gene & Cell Therapy
- Monoclonal Antibody
- Small Molecule
- Virus & Vaccine
- Others
- Phase
- Pre-Clinical
- Phase I
- Phase I/II
- Phase II
- Phase II/III
- Phase III
- Pre-Registration
List of Companies Mentioned:
The following companies and organizations have been mentioned in the pipeline:
AbbVie
Adaptimmune Agenus Akeso Biopharma Altor BioScience Amgen Angimmune Ascend Biopharmaceuticals AstraZeneca Autotelic Biodesix Biogen Bioniz BioNTech Biosceptre Boehringer Ingelheim BPGbio (Berg Pharma) Bristol-Myers Squibb Celldex Therapeutics Celltrion CEL-SCI Corporation Checkmate Pharmaceuticals (Acquired by Regeneron) Checkpoint Therapeutics DermBiont DFB Soria Dr. Reddy’s Laboratories Eisai |
Elevar Therapeutics (Previously LSK BioPharma)
Elios Therapeutics Equillium (Bioniz) Eterna Therapeutics Exelixis Galectin Therapeutics Genentech (Roche) GSK (GlaxoSmithKline) Hanmi Pharmaceutical HiberCell Huya Bioscience Immunocore Innate Pharma Innovent Biologics Inovio Pharmaceutical Iovance Biotherapeutics Ipsen Kintara Therapeutics Kowa Krystal Biotech LadRx Corporation Lumos Pharma (NewLink Genetics) MedImmune (AstraZeneca) Medivir Merck & Co Merck KGaA Moderna NanoCarrier |
Nanology
NantCell Neumedicines Novartis Oncolys Biopharma Oncolytics Biotech Oncotelic Ono Pharmaceuticals Pfizer Philogen Phio Pharmaceuticals Photogen Technologies Inc. Pierre Fabre Polaris Pharmaceuticals Polynoma Privo Technologies Provectus Biopharmaceuticals Pyxis Oncology Regeneron Pharmaceutical Replimune Roche (Ignyta) Sol-Gel Technologies Soligenix Summit Therapeutics Takara Bio Transgene TriSalus Life Sciences Ultimovacs Vidac Pharma |
Our Research & Services |
Company |
MoreSubscribe for Latest Updates
Privacy Policy Disclosures Contact Us: [email protected] © 2025 SNS Research |